GlycoBioSciences Revenue

About GlycoBioSciences

GlycoBioSciences Inc. is a pharmaceutical company exclusively devoted to the sale, licensing and development of therapeutic products based on our Ionic Polymer Matrix (IPMTM) technology. Our technology is covered by eleven in force US patents 1 UK patent, 1 Australian Patent, and 1 South African Patent. IPMTM Wound Gel has been approved for sale in the US by the FDA under four approved 510 (k)’s (as a medical device) K020325, K123113, K130781 & recently in March of this year the FDA cleared our K123193 510 (k) which covers our IPM Wound Gel product made with bio-fermented HA, and treats several types of wounds including diabetic wounds. Our study in for our IPM Wound Gel in 27 patients and on 53 wounds, yielded an 89% healing rate in hard to heal ulcers (study available on request). Ionic Polymer Matrix is a patented trans-dermal delivery technology utilizing a combination of a non-ionic polymer with a highly negatively charged polymer (Hyaluronic Acid) of specific molecular weight in a stable and PH balanced gel. This gel is capable of encapsulating other molecules (drugs i.e. sodium diclofenac, vitamins i.e. niacin). Such blended gel(s) applied topically to skin can be used for trans-dermal delivery of encapsulated molecules to targeted areas and release into systemic circulatory system. Blood and urine tests performed by us confirm the delivery and presence of these molecules. IPMTM Wound Gel is the Ionic Polymer Matrix Gel on its own and without any additional encapsulated molecules. It is our flagship product that is cleared in U.S. by FDA under four 510 k's (K020325, K123113, K130781 & K123193) covering wound, dermatitis, and post-surgical scaring indications.

View contact profiles from GlycoBioSciences